We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase 2b trial shows efficacy and safety of BCMA-directed mRNA CAR T-cell therapy in generalized myasthenia gravis, suggesting new treatment options.
77th American Academy of Neurology Annual Meeting, April 5-9, 2025, San Diego
No takes yet. Share an insight, caveat, or question.
Vu et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: